Study to Reduce Symptoms of Premature Beats With Ranolazine
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Investigate whether ranolazine, a novel anti-anginal agent with antiarrhythmic properties,
has a role in the management of symptomatic ventricular premature beats.